Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG-Reference-Cited by-同舟云学术

Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG

Published:2022-01 Issue:1 Volume:40 Page:9.e9-9.e17
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Subiela José Daniel,Faba Óscar Rodríguez,Aumatell Julia,Krajewski Wojciech,Calderón Julio,Parada Rubén,Huguet Jorge,Algaba Ferran,Breda Alberto,Palou Joan

Funder

Universitat Autònoma de Barcelona

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference24 articles.

1. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review;Casey;Eur Urol,2015

2. Situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes;Subiela;Eur Urol Focus.,2020

3. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study;Lamm;J Urol,2000

4. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials;Sylvester;J Urol,2005

5. European association of urology guidelines on non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update;Babjuk;Eur Urol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up;European Urology Focus;2023-03

2. Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models;Bladder Cancer;2022-12-14